[Courtesy of Genexine]
SEOUL -- Genexine, a clinical-stage biotechnology company, will cooperate with a domestic biotech company in developing an antibody that can neutralize the virus of COVID-19. Genexine has already been involved in a state-commissioned research consortium to develop a DNA vaccine material for COVID-19.
Y-Biologics, known for its expertise in antibody science, has discovered an antibody candidate. Genexine and Y-Biologics will jointly pay for the development of antibody treatments and share intellectual property rights. Genexine is responsible for the commercialization of products and technologies
South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. GC Pharma, a biotech company, has started producing products for clinical trials of GC5131A, an immunoglobulin drug based on plasma containing antibodies.
GC Pharma is working with the state-run National Institutes of Health to develop plasma treatment. As of July 20, 1,032 people have expressed their intention to donate plasma and GC Pharma has collected blood from 642 of them..
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
